Oral Antidiabetics

Type 2 diabetes isn’t a single failed switch — it is several failing systems at once. The core problem is insulin resistance (muscle, fat, and liver stop responding to insulin) layered on a slow decline in beta-cell output. Piled on top: the liver over-produces glucose (unrestrained gluconeogenesis), the gut’s incretin hormones (which normally boost insulin after a meal) are blunted, and the kidney reabsorbs too much glucose back into the blood instead of spilling it.

That "many levers" picture is the key to the whole class: each subclass of oral agent pulls a different lever, on a different organ. Understanding which organ a drug acts on tells you both how it lowers glucose and what its signature side effect will be. This is also why these drugs are often combined — they add up because they don’t overlap.

Metformin (a biguanide, and the first-line agent) works mainly at the liver, telling it to make less glucose, and improves insulin sensitivity in muscle. Crucially, it does not force insulin out, so on its own it does not cause hypoglycemia. Sulfonylureas (glipizide, glimepiride, glyburide) act on the beta cell, squeezing out insulin — but they do this regardless of the blood glucose level (glucose-*independent*), which is exactly why they *can* drop the sugar too low and cause hypoglycemia and weight gain.

The newer subclasses were designed around that problem. DPP-4 inhibitors ("-gliptins") raise the gut’s own incretin hormones, which stimulate insulin only when glucose is high (glucose-*dependent*) — so they rarely cause lows and are weight-neutral. GLP-1 receptor agonists ("-tides," mostly injectable, with oral semaglutide the exception) mimic that incretin more powerfully, adding satiety and slowed gastric emptying for real weight loss. SGLT2 inhibitors ("-flozins") ignore insulin entirely — they block the kidney’s glucose reabsorption so the patient excretes glucose in the urine. The -flozins and the -tides also carry proven heart-failure and kidney-protective benefits, which is why they’re now chosen for those conditions independent of glucose.

Each signature harm traces straight back to the organ the drug acts on. Sulfonylureas force insulin even when it isn’t needed → hypoglycemia and weight gain. Metformin’s footprint in the gut causes GI upset and diarrhea (take it with food, titrate slowly), and over years it can cause B12 deficiency; its rare but serious danger is lactic acidosis when the drug accumulates because the body can’t clear it (kidney failure, hypoxic states, IV contrast, excess alcohol) — the basis of its boxed warning.

SGLT2 inhibitors dump sugar into the urine, so the genital area becomes a breeding ground → yeast and urinary infections, and rarely Fournier gangrene; the osmotic diuresis causes volume depletion, and a metabolic shift toward ketones can cause euglycemic DKA — ketoacidosis with a near-normal glucose, which is easy to miss. DPP-4 inhibitors and GLP-1 agonists can cause pancreatitis; GLP-1 agonists carry a boxed warning for thyroid C-cell tumors (seen in rodents) and are contraindicated with a personal/family history of medullary thyroid cancer or MEN 2.